Today's Date
Atopic Dermatitis Dupilumab and anti-OX40 Treatment for Sustained Efficacy
(
ADDRESS
)
ITN Protocol #:
ITN082AD
Branded Name:
ADDRESS
Treatment Protocol #:
Therapeutic Area:
Allergy & Asthma
Current Status:
Withdrawn
Summary:
Randomized Double Blind Phase II Trial to Evaluate the Sustained Efficacy of Sequential Treatment with Dupilumab (anti-IL4Rα) followed by KHK4083 (anti-OX40) for Atopic Dermatitis
Clinical Operations Manager
Study Personnel:
